Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to performance under a transition services agreement

Seres预计将进行资本注入，包括预付款，使公司能够完全偿还债务，并将现金周转期延长至2025年第四季度，等待交易结束，并取决于过渡服务协议的执行情况

Future Company focus on advancement of SER-155 and other cultivated oral microbiome therapeutics for medically vulnerable patient populations with potential to address large commercial opportunities

未来的公司专注于为医学上脆弱的患者群体开发SER-155和其他培养的口腔微生物组治疗剂，并有可能解决巨大的商业机会

CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of Seres’ VOWST assets that will provide Nestlé Health Science with full VOWST product and related intellectual property rights.

马萨诸塞州剑桥市，2024年6月6日（环球通讯社）--领先的微生物治疗公司Seres Therapeutics，Inc.（纳斯达克：MCRB）今天宣布，它已与雀巢健康科学签订了一份不具约束力的谅解备忘录，出售Seres的VOWST资产，该资产将为雀巢健康科学提供完整的VOWST产品和相关知识产权。

Under the terms of the pending agreement, Seres is due to receive capital infusions, including an upfront payment. Seres expects to complete the transaction within the next 90 days, subject to the negotiation of definitive agreements, Seres’ shareholder approval, and other customary conditions..

根据未决协议的条款，Seres将接受资本注入，包括预付款。Seres预计将在未来90天内完成交易，但须遵守最终协议的谈判、Seres股东的批准和其他习惯条件。。

“We are proud of our success in bringing VOWST to patients as the first ever FDA-approved oral microbiome therapy, and following the anticipated transaction close, we will continue to work with Nestlé Health Science and our other partners to ensure a seamless transition and ongoing product availability,” said Eric Shaff, President and Chief Executive Officer of Seres.

Seres总裁兼首席执行官埃里克·沙夫（EricShaff）表示：“我们为成功将VOWST作为FDA批准的第一种口服微生物组疗法带给患者感到骄傲，在预期的交易结束后，我们将继续与雀巢健康科学和其他合作伙伴合作，以确保无缝过渡和持续的产品可用性。”。

“We plan to use the capital from this pending transaction to retire our existing debt facility and strengthen our balance sheet. These actions enable the Company to enter an exciting next phase as we move SER-155 and other wholly-owned cultivated microbiome therapeutic candidates forward to important milestones and we look forward to discussing these programs in greater detail later this year.

“我们计划利用这笔未决交易的资金来偿还现有债务，并加强我们的资产负债表。随着我们将SER-155和其他全资培养的微生物组治疗候选人推向重要里程碑，这些行动使公司能够进入一个令人兴奋的下一阶段，我们期待着今年晚些时候更详细地讨论这些计划。

Seres’ therapeutic candidates could benefit multiple underserved patient groups, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. Our approach could protect millions of medically vulnerable patients from life-threatening infections while addressing the global public health issue of antimicrobial resistance (AMR).”.

Seres的治疗候选人可能会使多个服务不足的患者群体受益，包括慢性肝病，癌症中性粒细胞减少症和实体器官移植患者。我们的方法可以保护数百万医学弱势患者免受危及生命的感染，同时解决全球公共卫生问题的抗菌药物耐药性（AMR）。”。

In July 2021, Seres entered a license agreement with Nestlé Health Science that granted a co-exclusive license to develop and commercialize VOWST. In April 2023, VOWST obtained FDA approval to prevent the recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI), followed by commercial launch in June 2023 led by Nestlé Health Science.

2021年7月，Seres与雀巢健康科学公司签订了一份许可协议，授予开发和商业化VOWST的独家许可。2023年4月，VOWST获得FDA批准，以预防复发性CDI（rCDI）抗菌治疗后成人艰难梭菌感染（CDI）的复发，随后于2023年6月由雀巢健康科学公司领导商业启动。

Under the pending agreement, Nestlé Health Science will obtain full ownership of the product. Seres will support the full transition of VOWST to Nestlé Health Science and continuity of the supply chain through a customary transition service agreement..

根据悬而未决的协议，雀巢健康科学将获得该产品的全部所有权。Seres将通过传统的过渡服务协议支持VOWST向雀巢健康科学的全面过渡以及供应链的连续性。。

Seres expects to use the capital from this transaction to fully retire its senior secured debt facility with Oaktree Capital Management, and support the further advancement of SER-155 and its other cultivated microbiome product candidates. Based on Seres' current cash, its future operating plans, and the capital expected to be obtained from the transaction, the Company anticipates being able to extend its cash runway into Q4 2025, subject to performance under the transition services agreement..

Seres预计将利用此次交易产生的资金，将其与Oaktree capital Management的高级担保债务授信全部注销，并支持SER-155及其其他培养微生物产品候选产品的进一步发展。根据Seres目前的现金、未来的运营计划以及预期从交易中获得的资本，该公司预计能够将其现金跑道延长至2025年第四季度，具体取决于过渡服务协议下的表现。。

About Seres Therapeutics

关于Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. VOWST™ obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science.

Seres Therapeutics，Inc.（纳斯达克：MCRB）是一家商业阶段公司，开发用于严重疾病的新型微生物组疗法。2023年4月，VOWST™获得美国食品和药物管理局（FDA）的批准，成为第一种口服微生物组治疗药物，用于预防复发性CDI抗菌治疗后成人艰难梭菌感染（CDI）的复发，并正在与雀巢健康科学（NestléHealth Science）合作进行商业化。

Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation. SER-155 has potential to reduce the incidence and severity of gastrointestinal and related bloodstream infections, and the incidence of acute graft-versus-host disease. For more information, please visit www.serestherapeutics.com..

Seres正在接受异基因造血干细胞移植的患者的1b期研究中评估SER-155。SER-155有可能降低胃肠道和相关血流感染的发生率和严重程度，以及急性移植物抗宿主病的发生率。欲了解更多信息，请访问www.serestherapeutics.com。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements about the financial terms, timing and likelihood of completing the sale of VOWST assets to Nestle; the sufficiency of cash and meeting terms of the agreement to fund operations; the use of proceeds of the transaction, including the ability to retire our senior secured debt facility; the timing and results of our clinical studies; future product candidates, development plans and commercial opportunities; operating plans and our future cash runway; and other statements which are not historical fact..

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明。本新闻稿中所有与历史事实无关的声明均应视为前瞻性声明，包括有关财务条款、完成向雀巢出售VOWST资产的时间和可能性的声明；现金充足，满足协议条款，为运营提供资金；交易收益的使用，包括注销我们的优先担保债务授信的能力；我们临床研究的时间和结果；未来的候选产品、开发计划和商业机会；运营计划和我们未来的现金跑道；以及其他非历史事实的陈述。。

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our history of operating losses; the restrictions in our debt agreement; our novel approach to therapeutic intervention; our reliance on third parties to conduct our clinical trials and manufacture our product candidates; the competition we will face; our ability to protect our intellectual property; and our ability to retain key personnel and to manage our growth.

这些前瞻性陈述基于管理层当前的期望。这些声明既不是承诺也不是保证，但涉及已知和未知的风险、不确定性和其他重要因素，这些因素可能导致我们的实际结果、业绩或成就与前瞻性声明中明示或暗示的任何未来结果、业绩或成就有实质性差异，包括但不限于以下内容：我们已经遭受重大损失，目前不盈利，可能永远不会盈利；我们需要额外资金；我们的经营亏损历史；我们债务协议中的限制；我们治疗干预的新方法；我们依靠第三方进行临床试验和生产候选产品；我们将面临的竞争；我们保护知识产权的能力；以及我们留住关键人员和管理增长的能力。

These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), on May 8, 2024, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.

在2024年5月8日提交给美国证券交易委员会（SEC）的10-Q表季度报告中，以及我们提交给SEC的其他报告中，在标题“风险因素”下讨论的这些和其他重要因素可能会导致实际结果与本新闻稿中的前瞻性声明所示结果存在重大差异。

Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release..

任何此类前瞻性声明均代表截至本新闻稿发布之日管理层的估计。虽然我们可能会选择在未来某个时候更新此类前瞻性声明，但我们不承担任何义务，即使随后的事件导致我们的观点发生变化。这些前瞻性声明不应被视为代表我们在本新闻稿发布日期之后的任何日期的观点。。